Crispr Therapeutics AG (CRSP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $56.37 (-1.67%), Market cap $4.59B, 52-week low–high $36.29 ~ $76.78.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for auto
Financial statements, price targets, institutional (13F) holdings and related news for Crispr Therapeutics AG are updated in real time on BlackAll Trade.
Crispr Therapeutics AG trades at $56.37 (-1.67%). Real-time quotes and charts are available on BlackAll Trade.
Crispr Therapeutics AG has a market cap of about $4.59B.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISP